Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$15.15
+1.7%
$20.38
$14.01
$33.33
$2.20B1.461.01 million shs922,545 shs
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
$23.37
-0.9%
$21.95
$15.19
$27.29
$2.57B-0.04488,113 shs1.38 million shs
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$3.66
+7.3%
$4.12
$3.02
$10.72
$620.45M1.652.28 million shs2.13 million shs
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$39.96
+2.1%
$45.91
$27.41
$60.90
$2.33B2.151.00 million shs767,294 shs
Unlock the Potential in Options Trading Cover

Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-6.65%-8.48%-27.65%-35.18%-28.76%
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
+0.94%+0.34%+23.52%-4.50%+5.74%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-6.83%-2.01%-8.82%-27.60%-62.69%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-0.51%-0.15%-15.32%-17.64%+10.07%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
4.1923 of 5 stars
4.51.00.04.71.82.50.0
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
2.694 of 5 stars
3.52.00.00.02.44.20.0
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.2752 of 5 stars
3.51.00.00.02.52.50.6
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
3.6625 of 5 stars
3.41.00.04.42.70.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
2.94
Moderate Buy$37.20145.54% Upside
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
3.00
Buy$43.3385.42% Upside
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
2.90
Moderate Buy$19.80440.98% Upside
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
2.70
Moderate Buy$54.4036.14% Upside

Current Analyst Ratings Breakdown

Latest RLAY, TWST, DNLI, and NAMS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/10/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$30.00 ➝ $28.00
3/7/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$41.00 ➝ $33.00
3/7/2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
3/5/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$38.00 ➝ $35.00
3/3/2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$41.00
3/3/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$50.00 ➝ $42.00
2/28/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
2/28/2025
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$80.00 ➝ $87.00
2/27/2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$47.00 ➝ $52.00
2/27/2025
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$46.00 ➝ $42.00
2/27/2025
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $18.00
(Data available from 3/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
$330.53M6.66N/AN/A$7.42 per share2.04
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
$45.56M56.33N/AN/A$3.50 per share6.68
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
$10.01M62.00N/AN/A$5.90 per share0.62
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
$330.19M7.22N/AN/A$7.64 per share5.23
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$145.22M-$2.57N/AN/AN/AN/A-32.94%-30.04%5/6/2025 (Estimated)
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
-$176.94M-$2.60N/AN/AN/AN/AN/AN/A5/14/2025 (Estimated)
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$341.97M-$2.39N/AN/AN/AN/A-45.75%-40.75%5/1/2025 (Estimated)
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$208.73M-$3.38N/AN/AN/A-59.76%-32.69%-25.25%5/1/2025 (Estimated)

Latest RLAY, TWST, DNLI, and NAMS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
2/27/2025Q4 2024
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
-$0.75-$0.67+$0.08-$0.67$12.75 millionN/A
2/26/2025Q4 2024
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
-$0.48-$0.95-$0.47-$0.95$3.30 million$12.77 million
2/26/2025Q4 2024
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
-$0.57-$0.45+$0.12-$0.45$5.53 millionN/A
2/3/2025Q1 2025
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
-$0.62-$0.53+$0.09-$0.53$86.96 million$88.70 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/AN/AN/AN/AN/A
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
N/AN/AN/AN/AN/A
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/AN/AN/AN/AN/A
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
N/A
9.98
9.98
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
N/A
10.61
10.61
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
N/A
18.42
18.42
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
0.03
4.96
4.62

Institutional Ownership

CompanyInstitutional Ownership
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
92.92%
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
89.89%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
96.98%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
N/A

Insider Ownership

CompanyInsider Ownership
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
7.90%
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
19.50%
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
4.32%
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
3.01%
CompanyEmployeesShares OutstandingFree FloatOptionable
Denali Therapeutics Inc. stock logo
DNLI
Denali Therapeutics
430145.22 million132.55 millionOptionable
NewAmsterdam Pharma stock logo
NAMS
NewAmsterdam Pharma
4109.82 million74.37 millionOptionable
Relay Therapeutics, Inc. stock logo
RLAY
Relay Therapeutics
330169.52 million160.15 millionOptionable
Twist Bioscience Co. stock logo
TWST
Twist Bioscience
99059.65 million57.86 millionOptionable

Recent News About These Companies

Twist Bioscience is Now Oversold (TWST)
TD Cowen Sticks to Their Buy Rating for Twist Bioscience (TWST)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Denali Therapeutics stock logo

Denali Therapeutics NASDAQ:DNLI

$15.15 +0.26 (+1.75%)
Closing price 04:00 PM Eastern
Extended Trading
$15.14 -0.01 (-0.03%)
As of 07:14 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

NewAmsterdam Pharma stock logo

NewAmsterdam Pharma NASDAQ:NAMS

$23.37 -0.21 (-0.89%)
Closing price 04:00 PM Eastern
Extended Trading
$23.38 +0.01 (+0.04%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Relay Therapeutics stock logo

Relay Therapeutics NASDAQ:RLAY

$3.66 +0.25 (+7.33%)
Closing price 04:00 PM Eastern
Extended Trading
$3.55 -0.11 (-3.01%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$39.96 +0.84 (+2.15%)
Closing price 04:00 PM Eastern
Extended Trading
$38.23 -1.73 (-4.33%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.